About this item
Highlights
- A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective.
- About the Author: IQBAL RAMZAN is Professor of Pharmaceutical Sciences at The University of Sydney's School of Pharmacy, having recently stepped down as Dean after 12 years (2006-2017).
- 320 Pages
- Medical, Pharmacy
Description
About the Book
"Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious successors (biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic and clinical utility. Pharmacists are the primary health care professionals who will provide advice to physicians, other health practitioners and patients on these drugs as governments and other third party payers attempt to contain their costs by introducing interchangeable products"--Book Synopsis
A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective.
- Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about
- Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence
- Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists
From the Back Cover
A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective.
- Explains what pharmacists need to discuss about the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients
- Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence
- Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists
About the Author
IQBAL RAMZAN is Professor of Pharmaceutical Sciences at The University of Sydney's School of Pharmacy, having recently stepped down as Dean after 12 years (2006-2017). Professor Ramzan is a recognized expert in drug pharmacokinetics/pharmacodynamics, has published 150 refereed papers, and has provided high level advice to the Australian Government on drug registration. He is an international leader in Pharmacy education and is a Past-President of the Asian Association of Schools of Pharmacy and the Council of Pharmacy Schools - Australia and New Zealand. Professor Ramzan is a pharmacist, holds a PhD from The University of Sydney, and has an academic career spanning over 40 years.